Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Etoposide, and Exisulind in Extensive Small Cell Lung Cancer
NCT00041054Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jun 2002
- Primary completion
- Aug 2004
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of exisulind in small cell lung cancer (SCLC), sponsored by Cancer and Leukemia Group B. Primary endpoint: Overall Survival Rate at 12 months. Started Jun 2002; status: completed.
02
Drugs
exisulind
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00041054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00041054.